An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer

Michele Bartoletti; Giorgio Giorda; Alessandra Viel; Mara Fornasarig; Adrian Zdjelar; Enrica Segatto; Roberto Sorio; Serena Corsetti; Simona Scalone; Milena Sabrina Nicoloso; Tania Pivetta; Emilio Lucia; Nicolò Clemente; Elisa Palazzari; Vincenzo Canzonieri; Fabio Puglisi

doi:10.3390/curroncol29080413

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer

Curr Oncol. 2022 Jul 22;29(8):5209-5212. doi: 10.3390/curroncol29080413.

Authors

Michele Bartoletti¹, Giorgio Giorda², Alessandra Viel³, Mara Fornasarig⁴, Adrian Zdjelar⁵, Enrica Segatto⁵, Roberto Sorio¹, Serena Corsetti¹, Simona Scalone¹, Milena Sabrina Nicoloso¹, Tania Pivetta^{1

6}, Emilio Lucia², Nicolò Clemente², Elisa Palazzari⁷, Vincenzo Canzonieri^{8

9}, Fabio Puglisi^{1

6}

Affiliations

¹ Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 33081 Aviano, Italy.
² Unit of Gynecologic Oncology Surgery, IRCCS CRO Aviano, National Cancer Institute, 33081 Aviano, Italy.
³ Unit of Functional Oncogenomics and Genetics, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
⁴ Unit of Oncologic Gastroenterology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
⁵ Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro di Riferimento Oncologico, Via Franco Gallini, 2, 33081 Aviano, Italy.
⁶ Department of Medicine, University of Udine, 33100 Udine, Italy.
⁷ Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
⁸ Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
⁹ Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy.

Abstract

Until recently, effective therapies for advanced endometrial cancer progressing to a platinum-based combination were lacking. In this setting, immunotherapy with anti PD-1/PDL-1 monoclonal antibodies is rising as a new paradigm in particular for patients with microsatellites instability/mismatch repair deficiency. In this case report, we describe an exceptional and rapid response to dostarlimab in a platinum refractory endometrial cancer patient with high disease burden harboring a mismatch repair deficiency.

Keywords: dostarlimab; endometrial cancer; immunotherapy; predictive biomarkers.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Brain Neoplasms
Colorectal Neoplasms
DNA Mismatch Repair
Endometrial Neoplasms* / drug therapy
Endometrial Neoplasms* / genetics
Female
Humans
Immune Checkpoint Inhibitors
Microsatellite Instability
Neoplastic Syndromes, Hereditary*
Platinum / therapeutic use
Programmed Cell Death 1 Receptor

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor
dostarlimab
Platinum

Supplementary concepts

Turcot syndrome

Grants and funding

This research received no external funding.